Impaired cardiac function including any of the following:\r\n* Myocardial infarction within  months of starting study drug\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an anti-hypertensive regimen)
A past medical history of other clinically significant cardiovascular disease (eg, uncontrolled hypertension, history of labile hypertension, history of poor compliance with an antihypertensive regimen).
Impaired cardiac function including any of the following:\r\n* Myocardial infarction within  months of starting study drug\r\n* A past medical history of clinically significant electrocardiography (ECG) abnormalities, including corrected QT (QTc)  ms or greater\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
EXCLUSION - PARTICIPANT: Clinically significant cardiac disease or impaired cardiac function, including any of the following: \r\n* Clinically significant and/or uncontrolled heart disease such as congestive heart failure (New York Heart Association grade >= ) uncontrolled hypertension, or clinically significant arrhythmia currently requiring medical treatment\r\n* Fridericia's correction formula (QTcF) >  msec for females, or >  msec for males, on screening electrocardiography (ECG) or congenital long QT syndrome\r\n* Acute myocardial infarction or unstable angina pectoris <  months prior to screening
Known impaired cardiac function including any of the following:\r\n* History or presence of clinically significant ventricular or atrial tachyarrhythmias;\r\n* Clinically significant resting bradycardia (<  beats per minute);\r\n* Myocardial infarction within  year of starting study drug;\r\n* Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
Cardiovascular disorders such as:\r\n* Inability to monitor the QT interval on electrocardiogram (ECG)\r\n* Complete left bundle branch block\r\n* Right bundle branch block plus left anterior or posterior hemiblock\r\n* Use of a ventricular-paced pacemaker\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* Clinically significant resting bradycardia (<  beats per minute)\r\n* Corrected QT interval (QTc) >  msec on baseline ECG; if QTc >  msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction within  months prior to starting study\r\n* History of unstable angina within  months prior to study entry\r\n* Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)\r\n* History of or presence of clinically significant ventricular or atrial tachyarrhythmias
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) <  beats per minute (bpm); patients with pacemakers are eligible if HR >=  bpm\r\n* Screening electrocardiogram (ECG) with a corrected QT (QTc) >  msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina =<  months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: \r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) <  beats per minute (bpm); patients with pacemakers are eligible if HR >=  bpm\r\n* Screening electrocardiogram (ECG) with a corrected QT (QTc) >  msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Myocardial infarction or unstable angina =<  months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within  months\r\n* Acute myocardial infarction within  months\r\n* Corrected QT interval (QTc) >  msec on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any of the following: history or presence of ventricular tachyarrhythmia; presence of unstable atrial fibrillation (ventricular response >  beats per minute [bpm]); patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria; clinically significant resting bradycardia (<  bpm); angina pectoris or acute myocardial infarction =<  months prior to starting study drug; other clinically significant heart disease (e.g., symptomatic congestive heart failure; uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within  months\r\n* Acute myocardial infarction within  months\r\n* Fridericia QT (QTcF) >  msec for males and >  msec for females on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function including any one of the following:\r\n* Inability to monitor the QT interval on electrocardiogram (ECG)\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* Clinically significant resting brachycardia (<  beats per minute)\r\n* QTc >  msec on baseline ECG; if QTc >  msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction within  months prior to starting study\r\n* Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)\r\n* History of or presence of clinically significant ventricular or atrial tachyarrhythmias
A past medical history of other clinically significant cardiovascular disease - e.g., uncontrolled hypertension, history of labile hypertension or history of poor compliance with an antihypertensive regimen
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: \r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible) \r\n* Any history of ventricular fibrillation or torsade de pointes \r\n* Bradycardia defined as heart rate (HR) <  beats per minute (bpm); patients with pacemakers are eligible if HR >=  bpm\r\n* Screening electrocardiogram (ECG) with a Fridericia's correction formula (QTcF) >  msec (QTcF = QT/^ square root of RR); if potassium, magnesium, or calcium blood levels are below normal limits, consider repeating ECG after correction of these electrolytes\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block) \r\n* Patients with myocardial infarction or unstable angina =<  months prior to starting study drug \r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function including any of the following:\r\n* Congenital long QT syndrome or a known family history of long QT syndrome;\r\n* Corrected QT (QTc) >  msec;\r\n* History or presence of clinically significant ventricular or atrial tachyarrhythmias;\r\n* Clinically significant resting bradycardia (<  beats per minute); \r\n* Myocardial infarction within  year of starting study drug;\r\n* Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
Impaired cardiac function including any of the following:\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* History or presence of clinically significant ventricular or atrial tachyarrhythmias\r\n* Clinically significant resting bradycardia (<  beats per minute)\r\n* Inability to monitor the QT interval by electrocardiogram (ECG)\r\n* Corrected QT (QTc) >  msec on baseline ECG; if QTc >  and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction within  year of starting study drug\r\n* Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
Impaired cardiac function or clinically significant cardiac diseases, history of arrhythmia (including ventricular fibrillation or torsade de pointes), bradycardia <  beats per minute (bpm), screening electrocardiogram (ECG) with prolonged corrected QT (QTc) (>  msec), uncontrolled hypertension or any history or presence of sustained ventricular tachyarrhythmia
Impaired cardiac function including any of the following:\r\n* Myocardial infarction within  months of starting study drug;\r\n* A past medical history of clinically significant ECG abnormalities\r\n* Other clinically significant heart disease (e.g. uncontrolled congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an anti-hypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following: a) angina pectoris within  months; b) acute myocardial infarction within  months; c) QT interval corrected with the Fridericia formula (QTcF) greater than  msec for males and greater than  msec for females on the screening electrocardiogram (ECG); d) a past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome; e) other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within  months\r\n* Acute myocardial infarction within  months\r\n* Corrected Fridericia's QT (QTcF) >  msec for males and >  msec for females on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* New York Heart Association classification IV cardiovascular disease or symptomatic class III disease \r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Known significant cardiac abnormalities, including:\r\n* History or presence of sustained ventricular tachyarrhythmia (participants with a history of atrial arrhythmia are eligible but should be discussed with Dr. Laubach prior to enrollment)\r\n* Any history of ventricular fibrillation or torsades de pointes\r\n* Bradycardia defined as heart rate (HR) <  beats per minute (bpm); participants with pacemakers are eligible if HR >=  bpm\r\n* QTcF interval >=  milliseconds on screening electrocardiogram (ECG);\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Participants with myocardial infarction or unstable angina =<  months prior to starting study drug\r\n* Other clinically significant heart disease (e.g. congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any of the following:\r\n* History or presence of ventricular tachyarrhythmia\r\n* Presence of unstable atrial fibrillation (ventricular response >  bpm) (NOTE: patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria)\r\n* Clinically significant resting bradycardia (<  bpm)\r\n* Angina pectoris or acute myocardial infarction =<  months prior to registration\r\n* Other clinically significant heart disease (e.g., symptomatic congestive heart failure; uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen)
Impaired cardiac function including any of the following:\r\n* Screening electrocardiogram (ECG) with a corrected QT interval (QTc) >  msec \r\n* Bradycardia defined as heart rate (HR) <  beats per minute (bpm)\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina <  months prior to starting study drug\r\n* Congestive heart failure (CHF) New York (NY) Heart Association class III or IV
Impaired cardiac function including any one of the following:\r\n* Inability to monitor the QT interval on electrocardiogram (ECG)\r\n* Congenital long QT syndrome or a known family history of long QT syndrome\r\n* Clinically significant resting brachycardia (<  beats per minute)\r\n* Corrected QT (QTc) >  msec on baseline ECG; if QTc >  msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction =<  months prior to starting study\r\n* Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)\r\n* History of or presence of clinically significant ventricular, atrial tachyarrhythmias or ejection fraction cutoff\r\n* Left ventricle ejection fraction < %\r\n* History of, congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* With permanent cardiac pacemaker\r\n* Resting bradycardia defined as <  beats per minute\r\n* Corrected QT using Fridericia's method (QTcF) >  msec on screening electrocardiogram (ECG)\r\n* Complete left bundle branch block, bifascicular block\r\n* Any clinically significant ST segment and/or T-wave abnormalities\r\n* Presence of unstable atrial fibrillation (ventricular response rate >  beats per minute [bpm]); patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria\r\n* Symptomatic congestive heart failure (New York Heart Association [NYHA] class III-IV)
Impaired cardiac function including any of the following:\r\n* Congenital long QT syndrome or a known family history of long QT syndrome;\r\n* History or presence of clinically significant ventricular or atrial tachyarrhythmias\r\n* Clinically significant resting bradycardia (<  beats per minute) \r\n* Inability to monitor the QT interval by electrocardiogram (ECG)\r\n* Corrected QT interval (QTc) >  msec on baseline ECG; if QTc >  and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc\r\n* Myocardial infarction within  year of starting study drug\r\n* Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: history or presence of sustained ventricular tachyarrhythmia; any history of ventricular fibrillation or torsade de pointes; bradycardia defined as heart rate (HR) <  beats per minute (bpm); patients with pacemakers are eligible if heart rate (HR) >=  bpm; screening ECG with a corrected QT using Fridericia's formula (QTcF) >  msec, right bundle branch block + left anterior hemiblock (bifascicular block), patients with myocardial infarction or unstable angina =<  months prior to starting study drug, other clinically significant heart disease (e.g., congestive heart failure [CHF] New York Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within  months\r\n* Acute myocardial infarction within  months\r\n* QT interval corrected using Fridericias formula (QTcF) >  msec for males and >  msec for females on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: * History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible) * Any history of ventricular fibrillation or torsade de pointes * Bradycardia defined as heart rate (HR)<  bpm. Patients with pacemakers are eligible if HR >/=  bpm. * Screening electrocardiogram (ECG) with a corrected QT interval (QTc) or QTcF >  msec * Right bundle branch block + left anterior hemiblock (bifascicular block) * Patients with myocardial infarction or unstable angina </=  months prior to starting study drug * Other clinically significant heart disease (e.g., Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Other clinically significant heart disease (e.g. congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Other clinically significant heart disease (i.e., Grade ? hypertension, history of labile hypertension, or poor compliance with an anti-hypertensive regimen)
New York Heart Association (NYHA) cardiac class - heart disease as well as impaired cardiac function defined as: left ventricular ejection fraction (LVEF) < % as determined by multigated acquisition scan (MUGA) scan or electrocardiogram; complete left bundle branch block; use of cardiac pacemaker; ST depression of >  mm in  or more leads and/or T wave inversions in  or more continuous leads; congenital long QT syndrome; history of, or presence of significant ventricular or atrial tachyarrhythmias; clinically significant resting bradycardia (<  beats per minute [bpm]); corrected QT (QTc) >  msec on screening electrocardiogram (ECG) (using the Fridericia QTc [QTcF] formula); right bundle branch block plus left anterior hemiblock, bifascicular block; myocardial infarction within  months prior to starting AMN (nilotinib); unstable angina diagnosed or treated within the past  months; other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, history of arrhythmia (including ventricular fibrillation or torsade de pointes), bradycardia <  beats per minute (bpm), screening electrocardiogram (ECG) with prolonged corrected QT (QTc) or uncontrolled hypertension
Other clinically significant heart disease (e.g., congestive heart failure (CHF) New York (NY) Heart Association class II or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Other clinically significant heart disease (e.g., CHF NY Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).
Impaired cardiac function or significant heart disease, including any one of the following:\r\n* Angina pectoris within  months\r\n* Acute myocardial infarction within  months\r\n* Corrected QT (QTc) >  msec on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* Other clinically significant heart disease (e.g. heart failure, uncontrolled/labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) <  beats per minute (bpm); patients with pacemakers are eligible if resting HR >=  bpm\r\n* Screening electrocardiogram (ECG) with a corrected QT with Fridericia's formula (QTcF) >  msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina =<  months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following: congestive heart failure, angina pectoris within  months, acute myocardial infarction within  months, Fridericia corrected QT interval (QTcF) >  milliseconds (msec) for males and >  msec for females on the screening electrocardiogram (ECG), history of clinically significant ECG abnormalities, family history of prolonged QT-interval syndrome, or other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment)\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) <  beats per minute (bpm); patients with pacemakers are eligible if HR >=  bpm\r\n* Screening electrocardiogram (ECG) with a QTc >  msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina =<  months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Any of the following concurrent severe and/or uncontrolled medical conditions that could compromise participation in the study: \r\n* ST depression or elevation of >= . mm in  or more leads\r\n* Congenital long QT syndrome\r\n* History or presence of sustained ventricular arrhythmias or atrial fibrillation\r\n* Clinically significant resting bradycardia (<  beats per minutes)\r\n* Corrected QT interval (QTc) >  msec on screening electrocardiogram (ECG)\r\n* Complete left bundle branch block\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Unstable angina pectoris =<  months prior to starting study drug\r\n* Acute myocardial infarction =<  months prior to starting study drug\r\n* Other clinically significant heart disease such as congestive heart failure requiring treatment (New York Heart Association [NYHA] class III or IV) or uncontrolled hypertension (please refer to World Health Organization [WHO]-International Society of Hypertension [ISH] guidelines)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: history or presence of sustained ventricular tachyarrhythmia; any history of ventricular fibrillation or torsade de pointes; bradycardia defined as heart rate (HR) <  beats per minute (bpm); patients with pacemakers are eligible if HR >=  bpm; screening electrocardiogram (ECG) with a corrected QT interval (QTc) >  msec; right bundle branch block + left anterior hemiblock (bifascicular block); patients with myocardial infarction or unstable angina =<  months prior to starting study drug; other clinically significant heart disease (e.g., congestive heart failure [CHF] New York [NY] Heart Association class III or IV, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Impaired cardiac function or clinically significant heart disease, including any one of the following:\r\n* Angina pectoris within  months\r\n* Acute myocardial infarction within  months\r\n* Corrected QT (QTc) >  msec for males and >  msec for females on the screening electrocardiogram (ECG)\r\n* A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome\r\n* Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor adherence with an antihypertensive regimen)
Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:\r\n* Any history of ventricular fibrillation or torsade de pointes\r\n* Bradycardia defined as heart rate (HR) <  beats per minute (bpm); patients with pacemakers are eligible if HR >=  bpm\r\n* Screening electrocardiogram with a QT corrected for Fridericia's formula (QTcF) >=  msec\r\n* Right bundle branch block + left anterior hemiblock (bifascicular block)\r\n* Patients with myocardial infarction or unstable angina =<  months prior to starting study drug\r\n* Other clinically significant heart disease (e.g., Classification of Heart failure [CHF] New York Heart Association class III or IV, uncontrolled hypertension) as per discretion of principal investigator and/or treating physician\r\n* Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug with the exception of drugs that are required for hematopoietic cell transplantation (HCT) patients
